NCT03481842View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 10, 2021

Primary Completion Date

October 10, 2021

Study Completion Date

October 10, 2021

Conditions
EndometriosisEndometriosis OvaryEndometriosis ExternaEndometriosis, Rectum
Interventions
BIOLOGICAL

Linifanib

in a minimally sufficient therapeutic dose

DRUG

BIBW2992

in a minimally sufficient therapeutic dose

DRUG

Axitinib

in a minimally sufficient therapeutic dose

Trial Locations (1)

4057

BioGene Pharmaceutical Ltd., Basel

Sponsors
All Listed Sponsors
lead

BioGene Pharmaceutical Ltd.

INDUSTRY

NCT03481842 - Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis | Biotech Hunter | Biotech Hunter